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EDITORIAL REVIEW
Apoptosis, nucleosomes, and nephritis in 
systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease 
that is characterized by the production of antinuclear autoanti­
bodies. The serological hallmark of SLE is the presence of 
antibodies against double-stranded DNA. It is generally assumed 
that these anti-DNA antibodies participate in the development of 
lesions in this disease. The primary event inducing the formation 
of anti-DNA antibodies has always been puzzling, since it has 
been very difficult to demonstrate the presence of free DNA in 
serum of SLE patients [1]. Furthermore, native DNA is usually 
considered non-immunogenic [2, 3]. In recent years, several 
studies have been published which suggest that not DNA itself, 
but DNA complexed to histones (nucleosomes) is the immuno­
genic particle involved both in the induction of pathogenic 
anti-DNA antibodies, and in the pathophysiology of SLE.
In eukaryotic cells, DNA is packed in the nucleus in the form of 
chromatin. In chromatin, adjacent nucleosomes are linked by 
about 60 bp of DNA. Nucleosomes are the fundamental repeating 
units of the chromatin string, and are responsible for the compac­
tion of DNA. Each nucleosome is built up by eight core histone 
molecules (forming the histone octamer), one histone HI mole­
cule and 146 bp of DNA [4], as shown in Figure 1.
Lately, it has become evident that at least in certain murine 
models of SLE (Ipr and gld mice), and perhaps also in SLE 
patients as well, the process of apoptosis is aberrant. Apoptosis 
(programmed cell death) results in fragmentation of the nucleus 
by internucleosomal cleavage of the chromatin. Normally, these 
apoptotic cells are phagocytosed rapidly, but if this does not occur 
nucleosomes may be released. On the other hand, apoptosis of 
maturing T cells is involved in establishing and maintaining 
tolerance, and therefore a disturbed apoptosis may cause a 
breakdown of tolerance. These recent data provide elements for a 
new concept of SLE, both for the induction as well as for the 
effector phase of the disease. We will first review the evidence for 
disturbed apoptosis in SLE, and then discuss how this relates to 
the immune response against nucleosomes. Subsequently, the 
significance of nucleosomes for the disease manifestations of SLE 
(with emphasis on glomerulonephritis) will be discussed.
Dysregulation of apoptosis in SLE
The term “apoptosis” was first used in 1972 to describe the 
process in which cells undergo several morphological changes, 
including condensation and fragmentation of the nucleus without 
disruption of the plasma membrane [5], It was later shown that 
activation of an endogenous nuclease is involved in the inter nu-
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cleosomal cleavage of chromatin [6]. The induction of apoptosis is 
under strict regulation by a variety of factors, including signals 
from surrounding cells. With respect to T cells, for example, both 
cytokines (such as interleukin-1, interleukin-2, interferon-y) and 
costimulatory molecules (like ICAM-1, VCAM-1, LFA-3 and B7) 
present on antigen-presenting cells determine whether a T ceil is 
driven to apoptosis or to cell proliferation [7-10]. Once a cell has 
become apoptotic, it should be removed in a rapid and efficient 
manner while still intact, to prevent the release of potentially toxic 
cell contents. This removal of apoptotic cells occurs by phagocy­
tosis. Macrophages are the most important effector cell in this 
respect, but other cell types like epithelial cells apparently can 
also ingest neighboring cells undergoing apoptosis. Several differ­
ent receptors on the phagocyte surface may be involved in this 
process, such as phosphatidylserine receptor and thrombospondin 
receptors [11]. The morphology of apoptotic cells in tissues and in 
vitro has been described in detail [12, 13].
It has been very difficult to demonstrate the presence of free 
DNA in serum from SLE patients, but when DNA was found it 
occurred in the form of (oligo)nucleosomes [1]. A potential 
source for these nucleosomes are apoptotic cells, since nucleo­
somes were spontaneously released from cultured normal murine 
spleen cells, whereas this process did not occur when apoptosis 
was blocked with zinc sulfate [14], Also during culture of human 
lymphocytes nucleosome release occurred, which was strongly 
correlated with the degree of lymphocyte apoptosis [15]. It is, 
however, not precisely known how nucleosomes are released from 
apoptotic cells. It is conceivable that in some cases these nucleo­
somes derive from apoptotic bodies. These appear at the cell 
surface of several cell types during apoptosis as a result of 
packaging of cellular components as membrane-bounded blebs. 
After their budding from the cell, apoptotic bodies are usually 
rapidly ingested by phagocytes. Some of these apoptotic bodies 
contain chromatin [13]. In a recent study on UV-injured kerati- 
nocytes, it was demonstrated that some of the apoptotic bodies 
contained nucleosomes, ribonucleoproteins (that are also targets 
of autoantibodies in SLE), and in addition fragments of the 
endoplasmatic reticulum or the nuclear membrane [16]. Nucleo­
somes may, after their release from apoptotic cells, also adhere to 
specific “nucleosome receptors” present on the surface of viable 
cells [17,18]. In contrast to the programmed process of apoptosis, 
cell death by necrosis is a more random process of cellular 
destruction [12, 13] that is not expected to yield intact nucleoso- 
mal particles.
In recent years it has become evident that, at least in certain 
murine models, SLE is directly linked to a defect in apoptosis. We 
will first discuss the data obtained in lupus-prone and transgenic 
mice, and then address this question for human SLE. In mice, the 
Ipr and gld genes provide single gene models of systemic autoim­
munity (including the formation of anti-dsDNA antibodies).
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Fig. 1. Diagram showing how the nucleosome is built up by eight histone 
proteins (4 hot nodimers of H2A, H2B, H3, and H4) and two superhelical 
turns of 146 bp of DNA. The N-terminal parts of the histone molecules 
(approximately one third of the total molecule) contain positively charged 
residues which are located on the outside of the nucleosome. Histone H I, 
which is located on the outside of the nucleosome, is not shown in this 
diagram.
Although expression of the Ipr gene in both B and T cells is 
required for autoantibody production in Ipr mice [19, 20], the 
molecular basis of the Ipr syndrome became only apparent when 
Watanabe-Fukunaga et al [21] demonstrated that Ipr mice lack the 
expression of the Fas antigen. The Fas molecule (also known as 
APO-i, and designated CD95) belongs to the TNF receptor 
family, and is a cell-surface receptor that mediates apoptosis. The 
aberrant transcription of the Fas gene in Ipr mice is caused by the 
insertion of a retroviral sequence in an intron [22-24]. Early 
replacement of the Ipr gene by the normal Fas gene will correct 
the accelerated autoimmune disease in these mice [25]. These 
findings demonstrate that in this model there is a causal relation­
ship between dysregulation of apoptosis and autoimmune disease. 
The natural ligand for Fas has recently been cloned; it is a 
transmembrane protein and a member of the TNF family [26]. 
The gid mouse strain has a mutation of the Fas ligand gene [27]. 
It therefore appears that either a defect in the receptor (Ipr) or its 
ligand (gld) causes systemic autoimmunity. How does the defect in 
the Fas antigen cause autoimmunity in Ipr mice? In view of the 
important role of apoptosis in shaping the T cell repertoire by 
negative selection, one is inclined to think that a defective Fas 
antigen would cause aberrant thymic selection. It appears, how­
ever, that thymic selection of CD4+ or CD8H- T cells in these 
mice proceeds normally [28], In contrast, both subsets of mature 
T cells exhibit decreased apoptosis in response to antigen stimu­
lation and therefore it has been suggested that autoimmunity in 
this model results from a failure of peripheral tolerance [29, 30]. 
Also in gld mice, the T cell defect apparently is contained within 
the compartment of activated, mature T cells rather than in the 
thymus [31], It seems probable that the defective Fas gene in Ipr 
mice may also cause a decreased antigen-inuuced apoptosis of 
mature autoimmune B cells [21]. It is important, however, to 
realize that even in Ipr mice other genes are involved as well [32]. 
Since MRL/+ mice (which lack the Ipr gene) also develop lupus 
(although to a lesser extent, and later in life), it must be concluded 
that Ipr accelerates rather than causes the disease. In other murine 
models of SLE? such as NZB/W mice, no abnormalities of the Fas 
gene have been detected [22].
Apart from the iw  gene, there are several other genes involved 
in the regulation of apoptosis. There are pathways for the 
induction of apoptosis which are independent of the Fas antigen, 
such as the TNF receptor [33]. Furthermore, there are genes that 
decrease the susceptibility for apoptosis, such as the bcl-2 gene 
[34], The bcl-2 gene was first discovered in B cell lymphomas, 
which have a permanent high expression of the bcl-2 protein. 
When in transgenic mice bcl-2 was brought under the control of 
an immunoglobulin promotor, the number of B cells increased, 
and autoantibodies against nuclear antigens (including histone 
and DNA) were produced, resulting in immune complex glomer­
ulonephritis [35]. In another study with transgenic mice, it could 
be demonstrated that bcl-2 inhibits the clonal deletion of autore­
active B cells in the periphery but not in bone marrow [36]. In 
bcl-2 knockout mice, fulminant lymphoid apoptosis was observed, 
causing disappearance of the lymphoid system within four weeks 
after birth [37, 38], Recent studies have revealed that the bcl-2 
gene is a member of an expanding family of similar genes, some of 
which have the same effect as bcl-2 (protection against apoptosis), 
whereas others like box will increase the susceptibility for apop­
tosis [39]. The box protein can form a heterodimer with the bcl-2 
protein and in this way neutralise the effect of bcl-2. The bcl-2 
protein apparently exerts its protective effect by activating an 
anti-oxidant pathway in the cell [40]. Many stimuli inducing 
apoptosis are known to generate reactive oxygen species. The 
relative amounts of bax and bcl-2 in a cell may therefore deter­
mine the susceptibility of the cell for apoptosis,
In human SLE, no defects in expression or function of the Fas 
antigen have been found [41]. This does not imply, however, that 
apoptosis is completely normal in human SLE. Two phenomena 
have been described that may contribute to disturbed apoptosis in 
human SLE. First, serum levels of soluble Fas were found to be 
elevated in several SLE patients. Due to alternative splicing, the 
Fas encoded protein can also occur in a soluble form. Soluble Fas 
can inhibit apoptosis, since after injection in normal mice, it 
causes increased numbers of B cells and autoimmune features 
[42]. Secondly, in lymphocytes from SLE patients the expression 
of bcl-2 is increased [43]. This may be a reflection of in vivo 
activation, since lymphocyte activation is known to increase the 
transcription of bcl-2 [44]. Despite these increases of soluble Fas 
and intracellular bcl-2, lymphocytes from SLE patients display an 
increased rate of “spontaneous” apoptosis in vitro [15], as do 
lymphocytes from Ipr mice [45], One should be cautious, however, 
to extrapolate from these in vitro findings to the in vivo situation.
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It has been postulated that lymphocytes from Ipr mice may be 
“primed” for apoptosis, but prevented from dying in vivo, Once 
placed in culture in vitro, such cells would then rapidly die [45]* 
With respect to lymphocytes from SLE patients, the protective 
effect of soluble Fas in serum will be diminished or absent when 
cells are cultured in vitro. Furthermore, as mentioned above, the 
rate of apoptosis of SLE lymphocytes in response to antigenic 
stimulation is decreased [29, 30] instead of increased. It may be 
important in this respect to precisely define the subset of lympho­
cytes that is being studied (double-negative T cells, or CD4- 
positive T cells, or B cells), and their antigen specificity. It is 
conceivable that some cells in SLE patients (or lupus-prone mice) 
display an increased rate of apoptosis whereas for other cells 
(depending on cell type, activation state, and specificity) apoptosis 
may proceed at a decreased rate, or at the same rate as in normal 
individuals. Therefore, although the Fas antigen is normal in 
human SLE, apoptosis appears to be abnormal, as evidenced by 
an increased concentration of soluble Fas, an increased expression 
of bcl-2, and an increased rate of apoptosis when lymphocytes 
from SLE patients are cultured in vitro. It remains to be proven 
that the abnormalities of apoptosis observed in human SLE are a 
cause of disease (as appears to be the case in the murine SLE 
models discussed above) rather than a consequence.
Dysregulation of apoptosis can contribute to the pathogenesis 
of lupus nephritis in two different ways. First, apoptosis appears to 
be an important mechanism to induce tolerance of T cells towards 
self-antigens [46, 47], This implies that a disturbance in apoptosis 
may cause persistence of autoreactive T cells and in this way affect 
the magnitude of the anti-nucleosomal immune response. As 
discussed above, one of the consequences of a defective Fas 
antigen is breakdown of peripheral T cell tolerance. Secondly, 
autoreactive lymphocytes that have escaped apoptosis in response 
to autoantigen may be “primed” for apoptosis. Some of these cells 
may be induced to become apoptotic by other mechanisms 
(unrelated to Fas), Removal of such apoptotic lymphocytes may 
be less effective (depending on the microenvironment) than when 
apoptosis occurs by the “normal” (antigen-induced) mechanism. 
In this respect it may be relevant that within tissues phagocytosis 
of apoptotic bodies occurs rapidly, but not when they are formed 
in a fluid medium [13]. A  possibility that deserves further inves­
tigation is that in SLE patients phagocytosis of apoptotic cells 
(and apoptotic bodies) might be decreased. Although there are no 
published data yet on this subject, it has been known for a long 
time that in SLE there are profound defects in other forms of 
phagocytosis (such as complement-mediated phagocytosis in lu­
pus-prone mice [48], and Fc receptor-dependent phagocytosis in 
SLE patients [49]). If phagocytosis of apoptotic cells is indeed 
defective in SLE, this could also affect the persistence of non­
lymphoid apoptotic cells (such as UV-injured keratinocytes [16]).
Nucleosomes as immunogenic particles in SLE
In what way can dysregulation of apoptosis contribute to 
autoimmunity against nucleosomal antigens in SLE? What is the 
role of nucleosomes, and how are T lymphocytes (double-nega­
tive, or CD4+ cells) and B cells involved in this process? As 
discussed above, apoptosis is the most likely source of nucleo­
somes. Lymphocytes from SLE patients demonstrated an in­
creased rate of apoptosis in vino, and the number of apoptotic 
ceils in freshly isolated lymphocytes was also slightly increased 
[15]. If this reflects the in vivo situation, the increased number of
apoptotic lymphocytes might lead to the release of increased 
amounts of nucleosomes. One way that nucleosomes can evoke an 
immune response is by polyclonal activation of B cells. Both with 
murine and human lymphocytes, polyclonal B cell activation by 
nucleosomes has been demonstrated [14, 50], The secretion of 
interleukin-6 that was observed after interaction of nucleosomes 
with murine spleen cells [18] may further enhance this polyclonal 
B cell activation.
Although polyclonal B cell activation by nucleosomes may 
occur, there are many arguments in favor of the hypothesis that 
pathogenic anti-DNA antibodies are the result of an antigen- 
driven immune response (such as clonal expansion, IgG class 
switch, somatic mutations). T-helper (Th) cells are required for 
the production of these anti-DNA autoantibodies. Since there is 
an expanded population of double-negative T cells (CD3+, 
CD4—, CD8~) in SLE [51, 52], and because these cells exhibit a 
preferential use of distinct V/3 genes both in Ipr mice [51] and in 
humans [53], these cells might be involved in the initiation of 
autoimmune disease. Indeed, a/3 CD4-CD8- (as well as yS 
CD4-CD8-) T helper cell lines could be isolated from patients 
with active lupus nephritis [52, 54]. The large majority, however, 
of Th cells supplying help for production of pathogenic anti-DNA, 
are CD4+ cells and not double-negative cells [54]. Furthermore, 
recent experiments with MHC class II-deficient Ipr mice have 
demonstrated an important role for CD4+ Th cells, whereas 
double-negative T cells did not appear to be essential for initiating 
disease [55]. It was found in lupus-prone mice that only a fraction 
of autoreactive T cell clones can induce anti-DNA autoantibodies 
in vitro, and accelerate the development of lupus nephritis when 
transferred in vivo. The specificity of these pathogenic Th cells has 
been studied in some detail. Approximately 50% of them were 
specific for nucleosomal antigens. Importantly, nudeosome-spe- 
cific CD4+ T cells were not detectable in normal mice, but they 
were found in the spleens of lupus-prone mice as early as one 
month of age, long before any autoimmune manifestation. These 
nucleosome-specific Th cells not only augmented the anti-nucleo- 
some response of syngeneic B cells, but also the anti-histone and 
anti-DNA response. The importance of nucleosomes as immuno­
genic particles was underlined by the finding that injection of 
purified nucleosomes into preautoimmune mice could signifi­
cantly accelerate the development of glomerulonephritis [56].
An intriguing question in this respect is the nature of the 
epitope recognized by the pathogenic Th cell. These nucleosome- 
specific Th clones were not activated by free DNA or histones, the 
two components of nucleosomes. This result suggests that either 
nucleosomes are taken up more efficiently by antigen-presenting 
cells, or that critical Th cell epitopes in the histones are protected 
from degradation by being bound to DNA [56]. Another possibil­
ity is that after antigen processing of nucleosomes, MHC class II 
molecules present self-peptides that were previously cryptic. The 
possible significance of such cryptic epitopes for the induction of 
autoimmunity has recently been reviewed [57]. It has also been 
suggested that the presence of endoplasmatic reticulum or nu­
clear membrane within the apoptotic bodies causes an increased 
generation of reactive oxygen species which may induce oxidative 
modification of autoantigens. The unique peptide fragments 
generated in this way could then, in genetically susceptible 
individuals, be presented to Th cells and induce an autoimmune 
response [16].
Whatever the precise nature of the epitope recognized by the
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Dysregulation of apoptosis
Decreased phagocytosis?
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Activation of complement, glomerulonephritis
could interact with HS and that this interaction might lead to 
albuminuria by neutralization of charge or by eliciting an inflam­
matory reaction [73]. At the same time Schmiedeke et al [77] 
indeed showed that hi stone aggregates have a high affinity for the 
GBM. We subsequently showed in a rat kidney perfusion system 
that histones can mediate binding of subsequent perfused DNA 
and anti-DNA and induce subepithelial or subendothelial local­
ization of the antibody depending on the perfusion protocol [78]. 
We propose that nucleosomes act as planted antigens or as 
mediators for binding of autoantibodies to the GBM. Although 
nucleosomes have a pi of about 7, they contain many positively 
charged N-terminal regions which are located on the outside of 
the particle. It has even been shown that molecules with a net 
negative charge, but with cationic regions can bind to the GBM 
[79]. Indeed, we could show that nucleosome containing immune 
complexes are able to bind to the GBM, whereas the purified 
antibodies do not bind. Binding of such complexes to the GBM is 
illustrated at the ultrastructural level in Figure 2. The pathogenic 
potential of this binding was underlined by the fact that comple­
ment activation took place. Using heparinase perfusion prior to 
perfusion of nucleosome containing immune complexes, we could 
show that the ligand in the GBM was partly but not solely HS [68]. 
The exact composition of the nucleosomal material in the immune 
complex which mediates the binding to the GBM in vivo is not 
clear yet. In our studies we obtained immune complexes from 
hybridoma culture supernatants and found that the four core 
histones but not H i were present, and DNA in the complexes 
were predominantly the size of about 120 bp. The presence of 
antibody bound to the nucleosome seems to be a critical deter­
minant, since we found that perfusion of naked nucleosomes did 
not lead to a comparable binding to the GBM. Furthermore, the 
specificity of the bound antibody could be important for the 
overall pi of the complex, for instance anti-DNA and anti- 
nucleosome antibodies increase the pi of the complex and thereby 
the nephritogenicity. This concept is supported by the recent 
finding that pathogenic anti-DNA antibodies, which are able to 
bind to HS in the GBM via nucleosomes, harbor more charged 
amino acids (like arginine) than non-pathogenic anti-DNA anti­
bodies [80]. In this concept binding of anti-histone antibodies, by 
binding to the histone part of the nucleosome would both
Fig, 3, Proposed mechanisms linking 
dysregulation of apoptosis to lupus nephritis. 
Nucleosomes can be released from 
apoptotic cells (decreased phagocytosis 
might be a contributing factor). Persisting 
nucleosome-specific T cells can provide help 
for production of anti-nucleosome 
antibodies, Nucleosomes can mediate the 
binding of such antibodies to anionic 
structures in the GBM, such as heparan 
sulfate (HS).
decrease the pi and the nephritogenicity of the complex. This 
latter hypothesis is in line with the clinical observation that renal 
disease is rare in SLE-like syndromes characterized by the occur- 
rence of predominantly anti-histone antibodies as in drug induced 
lupus.
What are the data to support the significance of nucleosomes in 
vivol Since HS reactivity is a feature of immune complexes 
consisting of anti-nuclear autoantibodies and nucleosomal anti­
gens, anti'HS reactivity in plasma is an indirect way to identify the 
presence of these immune complexes. Anti-HS reactivity has been 
found to correlate with renal symptoms in lupus patients [81-83], 
although anti-HS reactivity was not present in every episode with 
renal manifestations [83], Further evidence for the role of these 
immune complexes comes from our observation that the staining 
for glomerular HS in both human [84] and murine [85] lupus 
nephritis is strongly reduced or even absent. Despite a nearly 
complete loss of HS staining in mice with heavy and prolonged 
albuminuria, glomerular HS content was unaltered. Therefore, we 
had to conclude that HS was masked by immunoreactants pre­
sumably containing nucleosomal antigens. More direct evidence 
for the involvement of nucleosomes in lupus nephritis is provided 
by studies showing both histones [86, 87] and DNA [88] in 
glomerular immune deposits in human and murine lupus nephri­
tis. In one study the deposition of histones was almost exclusively 
found in albuminuric mice [87], underlining the role of histones 
and nucleosomes in the development of albuminuria in these 
mice. These in vivo data therefore support the concept that 
nucleosomal material may mediate antibody binding to the GBM 
for which HS is a ligand.
In conclusion, both in human and murine lupus abnormalities 
in apoptosis have been described. This aberrant apoptosis may 
contribute to lupus nephritis by mechanisms that have been 
summarized in Figure 3. Binding of nucleosome containing com­
plexes to other basement membranes might lead to other organ 
manifestations of the disease. However, many questions remain to 
be answered. Future studies have to clarify the exact contribution 
of disturbed apoptosis in SLE. In addition studies are needed to 
identify the precise nature of the epitopes within the nucleosome 
recognized by auto-reactive T cells. Furthermore, the possibility 
should be studied that different epitopes within the nucleosome
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dictate the production of different auto antibodies (such as anti- 
histone, anti-DNA, anti-nucleosome). Finally the exact composi­
tion of the nucleosome and the nucleosome/autoantibody com­
plex determining affinity for the GBM should be clarified.
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